Kim Linton

accessibility text

Name

Kim Linton

Job title

Professor of Medical Oncology and Honorary Consultant

Email Address

the-christie.medicaloncology.lymphomasecretaries@nhs.net

Phone number

0161 446 3753

Qualifications

MBChB, PhD, FRCP

Specialities

Lymphoma

Responsibilities

  • Management of lymphoma
  • Academic research and teaching (The University of Manchester)

Professional biography

Kim Linton is a Professor of Medical Oncology at the University of Manchester and an Honorary Consultant at The Christie NHS Foundation Trust, one of Europe’s leading cancer centres. She also holds an honorary academic appointment at the University of Liverpool.

A recognised leader in lymphoma clinical research, Professor Linton oversees a portfolio of investigator-led and industry-sponsored clinical trials spanning early-phase, late-phase, and real-world studies. She holds senior roles in several national and international trials, including REFRACT, PETReA, RADAR, EPCORE NHL-1, FOUNDATION UK, BRAMBLE, and UNCOVER PLUS.

Her translational research focuses on the late effects of cancer treatment and biomarker development, and she co-leads the Living With and Beyond Cancer Theme within the NIHR Manchester Biomedical Research Centre. Current projects are evaluating lung cancer screening in Hodgkin lymphoma survivors through the SEARCH study, developing proteomic biomarkers for early detection of anthracycline-induced cardiotoxicity, and applying digital pathology for risk stratification in Follicular and Hodgkin lymphomas.

She holds several leadership roles, including Chair of the Low Grade Lymphoma Study Group (UK Lymphoma Group) and Scientific Secretary of the European Haematology Association Lymphoma Specialized Working Group. She chairs the Christie Lymphoma Group and the UK Blood Cancer Biobank Oversight Committee. She is a medical advisor for Lymphoma Action and a standing member of the Cancer Research UK Expert Review Group.

Professor Linton contributes to postgraduate education as Course Co-Lead for the MRes Oncology Systemic Therapy Module and lectures on the Oxford Lymphoma Management Course. She supervises PhD and MSc students and provides clinical and educational supervision for oncology trainees.

She is regularly invited to speak at scientific meetings and educational events and contributes to national and international guideline development through roles with NICE, the British Society for Haematology, and the European Hematology Association. She also serves as a clinical expert for technology appraisals and advisory boards.

Professor Linton has authored over 100 peer-reviewed publications. Among her most impactful contributions are studies published in The Lancet and Lancet Haematology on epcoritamab, a bispecific antibody therapy for relapsed/refractory B-cell lymphomas, and the MATRix-RICE regimen for secondary CNS lymphoma. Co-authored publications on Zanubrutinib in relapsed/refractory marginal zone lymphoma (Clinical Cancer Research), and survival outcomes in plasmablastic lymphoma (Blood) have also been widely cited. She recently published national BCSH guidelines for marginal zone and mantle cell lymphomas as well as review articles in follicular lymphoma.

Publications

The Christie Private Care

Prof. Linton also practises privately at The Christie Private Care